Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
February 27 2024 - 3:30PM
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage
biotechnology company with a mission to discover, develop and
deliver potentially curative therapies that address the underlying
causes of heart disease, today announced that company management
will participate in TD Cowen’s 44th Annual Health Care Conference
and Leerink Partners Global Biopharma Conference 2024. Details of
participation are as follows:
TD Cowen 44th Annual Health ConferenceFormat: Genetic Medicines
PanelDate: Tuesday, March 5Time: 2:10 PM ET – 3:10 PM ET
Leerink Partners Global Biopharma Conference 2024Format:
Fireside ChatDate: Tuesday, March 12Time: 10:40 AM ET – 11:10 AM
ET
The live presentations will be webcast and may be accessed from
the Investors section of Tenaya’s website. A replay of the webcasts
will be available on the Tenaya website for approximately 30 days
following each conference.
About Tenaya TherapeuticsTenaya
Therapeutics is a clinical-stage biotechnology company committed to
a bold mission: to discover, develop and deliver potentially
curative therapies that address the underlying drivers of heart
disease. Leveraging its integrated and interrelated Gene Therapy,
Cellular Regeneration and Precision Medicine platforms and
proprietary core capabilities, the company is advancing a pipeline
of novel therapies with diverse treatment modalities for rare
genetic cardiovascular disorders and more prevalent heart
conditions. Tenaya’s most advanced candidates include TN-201, a
gene therapy for MYBPC3-associated hypertrophic cardiomyopathy
(HCM), TN-401, a gene therapy for PKP2-associated
arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301,
a small molecule HDAC6 inhibitor being initially developed for
heart failure with preserved ejection fraction (HFpEF). Tenaya also
has multiple early-stage programs progressing through preclinical
development. For more information,
visit www.tenayatherapeutics.com.
Contacts |
Investors |
Michelle Corral |
Anne-Marie Fields |
VP, Corporate Communications and Investor Relations |
Stern Investor Relations |
IR@tenayathera.com |
Annemarie.fields@sternir.com |
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From May 2024 to Jun 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jun 2023 to Jun 2024